Compare Charles River Laboratories Intl. Inc (CRL) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while iShares 10 20 Year Treasury Bond ETF trades at $98.14. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | TLH | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Fixed Income |
52-Week High | $233.60 | $105.36 |
52-Week Low | $145.57 | $97.13 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
TLH stock trades at $97.98, down 0.53% today, with a bearish technical signal from moving averages but bullish oscillators. The company has announced dividends for H1-26 and H2-26, yet key financial ratios are unavailable. Recent news highlights broader market volatility from Fed policy uncertainty and geopolitical tensions.
The outlook is cautious due to missing fundamental data and bearish technicals. Risks include macroeconomic headwinds and lack of visibility on earnings. Investment opportunity hinges on future financial disclosures and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
